Rhizen Pharmaceuticals S.A. Announces Initiation Of A "First In Human" Phase-1 Trial Of RP6530, A Dual PI3K Delta/Gamma Inhibitor, In Patients With Hematological Malignancies
Published: Dec 06, 2013
La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation of a "first in human" Phase-1 study of RP6530, a dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, for the treatment of patients with advanced hematological malignancies. The study entitled "A Phase-I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in patients with Relapsed or Refractory Hematologic Malignancies" is designed primarily to establish the safety and tolerability of RP6530. Secondary objectives include clinical efficacy assessment and biomarker response to allow dose determination and potential patient stratification in subsequent expansion studies. The study will be conducted at San Raffael Institute, Milan, Italy with Dr. Andres Ferrari as the Principal Investigator.
Help employers find you! Check out all the jobs and post your resume.